Female (n = 248 ) | Males (n =94) | Test of sig. | p | |
---|---|---|---|---|
Disease duration | ||||
Mean ± SD. | 7.5 ± 5.3 | 10 ± 6.7 | U = 8828.0* | 0.001* |
Median (min.–max.) | 6 (2–23 ) | 7 (2.5–28 ) | ||
DAS Activity | ||||
Remission (<2.6) | 106 (42.7) | 28 (29.8) | χ2 = 85.379* | <0.001* |
Mild (2.6–3.2) | 20 (8.1) | 24 (25.5) | ||
Moderate (3.2–5.1) | 44 (17.7) | 30 (31.9) | ||
Severe activity (>5.1) | 78 (31.5) | 12 (12.8) | ||
Mean ± SD. | 5.5 ± 8.2 | 4.1 ± 1.9 | U = 11560.0 | 0.906 |
Median (min.–max.) | 2 (1–34 ) | 3.1 (0.5–7 ) | ||
HADs A | ||||
Normal (0–7) | 214 (86.3) | 78 (83.0) | χ2 = 7.705 | 0.071 |
Borderline (8–10) | 18 (7.3) | 4 (4.3) | ||
Abnormal (11–21( | 16 (6.5) | 12 (12.7) | ||
Mean ± SD. | 4.1 ± 3.2 | 3.3 ± 2.1 | U = 10496.0 | 0.148 |
Median (min.–max.) | 3 (0–15) | 3 (0–9) | ||
HADs D | ||||
Normal (0–7) | 136 (54.8) | 64 (68.1) | χ2 = 6.305* | 0.043* |
Borderline (8–10) | 52 (21.0) | 10 (10.6) | ||
Abnormal (11–21) | 60 (24.2) | 20 (21.3) | ||
Mean ± SD. | 8.9 ± 5.8 | 7.1 ± 4.9 | U = 11063.0* | 0.026* |
Median (min.–max.) | 6 (1–21) | 7 (0–19) | ||
HAQ score | ||||
No difficulty (0) | 68 (27.4) | 36 (38.3) | χ2 = 8.652* | 0.034* |
Some difficulty (1) | 68 (27.4) | 18 (19.1) | ||
Much difficulty (2) | 86 (34.7) | 24 (25.5) | ||
Unable to do (3) | 26 (10.5) | 16 (17 ) | ||
Mean ± SD. | 1.3 ± 1 | 1.2 ± 1.1 | U = 11116.0 | 0.491 |
Median (min.–max.) | 1 (0–3 ) | 1 (0–3 ) | ||
VAS score | ||||
No pain (0–4) | 18 (7.2) | 8 (8.5) | χ2 = 16.420* | < 0.001* |
Mild (5–44) | 110 (44.5) | 50 (53.2) | ||
Moderate (45–74) | 94 (37.8) | 16 (17.0) | ||
Severe (75–100) | 26 (10.5) | 20 (21.3) | ||
Mean ± SD. | 44.4 ± 23.6 | 36.7 ± 25.9 | U = 10464.0* | 0.043* |
Median (min.–max.) | 40 (0–95) | 35 (0–90) | ||
Joint deformity | ||||
No deformity | 144 (58.1) | 52 (55.3) | χ2 = 1.307 | 0.253 |
Deformity | 104(41.9) | 42 (44.7) | ||
Number of drugs | ||||
Monotherapy | 60 (24.2) | 20 (21.3) | χ2 = 3.535 | 0.316 |
Ditherapy | 94 (37.9) | 30 (31.9) | ||
Triple therapy | 52 (21) | 20 (21.3) | ||
Biological therapy | 42 (16.9) | 24 (25.5) |